This current study with a longer term follow‐up supports our practice change to collect A‐ALC ≥ 0.5 × 109 cells/kg in addition to CD34 to improve clinical outcomes for lymphoma patients undergoing APBHSCT. Here, CD34 is linked to lymphoma.